The First Toddlers Eligible for CRISPR Are Two Years Old
The FDA just approved a CRISPR gene therapy for kids as young as two, making Casgevy the first gene-editing treatment cleared for toddlers with sickle cell disease or beta thalassemia. The approval took just 53 days, and the implications stretch far beyond the 5,500 newly eligible children.
Picture a two-year-old. Tiny shoes, sippy cups, maybe a word or two in their vocabulary. Now picture that same kid getting a one-time genetic treatment that could cure a lifelong blood disease before they're old enough to remember having it.
That's not science fiction anymore. On July 1, the FDA expanded the approval of Casgevy, Vertex Pharmaceuticals' CRISPR-based gene therapy, to children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia. It's the first approved gene therapy for kids this young with either condition, and it signals a fundamental shift in how we think about treating genetic diseases: don't manage them for a lifetime; fix them before the damage starts.
From Twelve to Two
When Casgevy first won FDA approval back in December 2023, it was cleared for patients 12 and older. That was already historic (first CRISPR therapy ever approved, standing ovation, the whole deal). But it left out the kids who arguably need it most.
Sickle cell disease doesn't wait until adolescence to wreak havoc. Organ damage begins in infancy as fetal hemoglobin naturally declines and red blood cells start sickling. Beta thalassemia major typically shows up in the first few years of life, chaining kids to regular blood transfusions just to stay alive. By the time a child hits 12, years of cumulative damage have already piled up.
The new label now covers ages two and up for both conditions. Vertex estimates that roughly 5,500 additional children in the U.S. become eligible overnight. Think of it like finally opening the doors to the patients who were always first in line but kept getting told to wait.
The Data Behind the Decision
The FDA didn't just take a leap of faith. Vertex ran two Phase 3 pediatric trials, CLIMB-141 (for beta thalassemia) and CLIMB-151 (for sickle cell disease), enrolling children ages 2 to 11.
The results in the 5-to-11 age group were striking. In the sickle cell trial, went at least 12 consecutive months without a single severe pain crisis after infusion. Zero. For kids who previously experienced repeated vaso-occlusive crises (those agonizing episodes where sickled red blood cells block blood flow), that's a transformation.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
all eight evaluable patients
On the thalassemia side, all eight evaluable children achieved transfusion independence for 12 straight months, with a mean duration of 23.4 months. These are children who used to need blood transfusions every few weeks just to maintain adequate hemoglobin levels. Now they don't need any.
The safety profile looked like what you'd expect from the conditioning process: mucositis, febrile neutropenia, decreased appetite. Casgevy requires myeloablative conditioning with busulfan (essentially wiping out the patient's bone marrow to make room for the edited cells), so the side effects mirror what's seen in stem cell transplants. No new red flags emerged in the younger age group.
The Extrapolation Gamble That Paid Off
There's an interesting wrinkle in this approval. The clinical trials enrolled kids 5 to 11, but the FDA approved Casgevy down to age two. How?
The agency used something called pediatric extrapolation, basically concluding that if the therapy works in 5-to-11-year-olds and the underlying biology is the same in younger kids, there's good reason to believe it'll work in 2-to-4-year-olds too. The mechanism of action (editing a patient's own blood stem cells with CRISPR to boost fetal hemoglobin production) doesn't fundamentally change between a three-year-old and a seven-year-old.
It's a calculated bet, but not a reckless one. The FDA is requiring a new long-term safety monitoring study covering the expanded age range. They're also leaning on years of experience with bone marrow transplants in very young children, which show that earlier intervention generally produces better outcomes before organ damage accumulates.
53 Days From Filing to Approval
The speed here is worth noting. Vertex's supplemental application was filed on May 4, 2026. The FDA approved it on July 1. That's 53 days, in a process that typically takes 10 to 12 months.
The secret weapon: the Commissioner's National Priority Voucher (CNPV) pilot program, which fast-tracks products aligned with critical U.S. health priorities. Casgevy's pediatric expansion was the eighth approval under this program. Combined with its existing Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy designations, this application had basically every expedited lane the FDA offers.
The message from the agency is clear: getting curative therapies to sick kids faster is a priority, not just a talking point.
The Bigger Picture (and the Bigger Problem)
The clinical story is inspiring. The access story is complicated.
Globally, over 500,000 babies are born with sickle cell disease every year. An estimated 81,100 children under five died from SCD in 2021 alone, mostly in sub-Saharan Africa. For beta thalassemia, roughly 25,500 transfusion-dependent cases are born annually worldwide.
Meanwhile, Casgevy's commercial rollout has been deliberate. Vertex reported $43 million in Casgevy revenue in Q1 2026, with about 39 patients infused across all regions as of September 2025. William Blair analysts project $344 million in full-year 2026 Casgevy sales, and Vertex is guiding to roughly $500 million combined revenue from Casgevy and its pain drug Journavx this year.
Those numbers reflect a harsh reality: a one-time gene therapy requiring specialized treatment centers, myeloablative conditioning, and intensive follow-up isn't going to scale like a pill. The kids who need Casgevy most live in countries where safe blood transfusions are already hard to come by, let alone CRISPR-based cell editing.
Why This Moment Matters Anyway
It's tempting to dismiss this as a milestone for a privileged few. But approvals like this one move the entire field forward. Each pediatric gene therapy approval (Zolgensma for infants with spinal muscular atrophy, Lenmeldy for children with MLD, now Casgevy for toddlers with blood disorders) pushes the regulatory framework closer to a world where fixing genes early in life becomes standard care, not experimental care.
The FDA just told the world it's comfortable approving CRISPR-based gene editing in two-year-olds. That sentence would have been unthinkable a decade ago. The gap between "approved" and "accessible" remains enormous, but you can't close the second gap without crossing the first one.
Somewhere, there's a two-year-old who might never remember having sickle cell disease. That's the point.
4 min read
Pfizer Just Found a Way to Bring Color Back
Pfizer's oral pill ritlecitinib just cleared both Phase 3 trials for vitiligo, a condition with almost no approved treatments. If regulators agree, it would be the first oral therapy ever approved to bring color back to depigmented skin.
